Clene (NASDAQ:CLNN) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Clene (NASDAQ:CLNN) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $31.00 target price on the stock. HC Wainwright also issued estimates for Clene’s Q1 2025 earnings at ($1.11) EPS, Q2 2025 earnings at ($1.15) EPS, Q3 2025 earnings at ($1.28) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($4.92) EPS, FY2026 earnings at ($3.02) EPS, FY2027 earnings at $0.52 EPS and FY2028 earnings at $5.26 EPS.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $23.00 price target on shares of Clene in a research report on Monday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $55.25.

Clene Price Performance

Clene stock opened at $3.54 on Monday. Clene has a 12-month low of $3.37 and a 12-month high of $9.20. The stock has a market capitalization of $29.47 million, a PE ratio of -0.67 and a beta of 0.27. The firm has a 50 day simple moving average of $4.49 and a 200-day simple moving average of $4.88.

Clene (NASDAQ:CLNN) last issued its quarterly earnings results on Monday, March 24th. The company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). Clene had a negative net margin of 8,556.77% and a negative return on equity of 1,106.30%. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.13 million. On average, analysts forecast that Clene will post -5.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. SBI Securities Co. Ltd. acquired a new stake in Clene during the 4th quarter worth about $69,000. Fullcircle Wealth LLC purchased a new position in shares of Clene in the fourth quarter worth approximately $69,000. Renaissance Technologies LLC purchased a new position in shares of Clene in the fourth quarter worth approximately $96,000. Parsons Capital Management Inc. RI acquired a new stake in shares of Clene during the fourth quarter valued at approximately $194,000. Finally, Geode Capital Management LLC lifted its position in shares of Clene by 52.9% in the 4th quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after acquiring an additional 22,539 shares in the last quarter. Institutional investors own 23.28% of the company’s stock.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.